Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 8—August 2020

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Marie JaspardComments to Author , Nathalie Butel, Najoua El Helali, Dhiba Marigot-Outtandy, Helene Guillot, Gilles Peytavin, Nicolas Veziris, Bahram Bodaghi, Philippe Flandre, Gregoire Petitjean, Eric Caumes, and Valerie Pourcher
Author affiliations: Sorbonne Université, Paris, France (M. Jaspard, H. Guillot, N. Veziris, B. Bodaghi, E. Caumes, V. Pourcher); Assistance Publique–Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Paris (M. Jaspard, H. Guillot, E. Caumes, V. Pourcher); Assistance Publique – Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris (N. Butel, B. Bodaghi); Groupe Hospitalier Paris Saint Joseph, Paris (N. El Helali, G. Petitjean); Bligny Medical Center, Briis sous Forges, France (D. Marigot-Outtandy); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris (G. Peytavin); Université Paris Diderot, Sorbonne Paris Cité, Paris (G. Peytavin); Assistance Publique–Hôpitaux de Paris, Hôpitaux Universitaires de l’Est Parisien, Paris (N. Veziris); Institut Pierre Louis Institute d’Épidémiologie et de Santé Publique, Paris (P. Flandre, E. Caumes, V. Pourcher)

Main Article

Table 1

Sociodemographic and medical characteristics of 57 patients who received linezolid for multidrug-resistant tuberculosis, Pitié-Salpêtrière Hospital, Paris, France, 2011–2016*

Characteristic Value
Age, y, median (IQR)
35 (26–39)
M 39 (68)
18 (32)
Country or region of origin
Georgia 36 (63)
Other Eastern Europe and Russia 8 (14)
Africa† 5 (9)
Asia‡ 5 (9)
3 (5)
History of treated TB 37 (65)
History of isoniazid-based regimen 23 (40)
History of linezolid-based regimen
HIV infection 5 (9)
Hepatitis B surface antigen–positive 1 (2)
Hepatitis C 24 (42)
Diabetes mellitus
2 (4)
History of intravenous drug use 20 (35)
Opioid substitution therapy, methadone or buprenorphine 12 (21)
Alcohol consumption
8 (14)
Body mass index at first visit, median (IQR), kg/m2 20.1 
Albumin level at first visit, median (IQR), g/L 34 (30–38)

*Values are no. (%) unless otherwise indicated. IQR, interquartile range; TB, tuberculosis.
†One from Algeria, 1 from Cameroon, 1 from Democratic Republic of the Congo, 2 from Côte d’Ivoire.
‡Three from China, 2 from Tibet.

Main Article

Page created: June 12, 2020
Page updated: July 17, 2020
Page reviewed: July 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.